Business Wire

Strong Customer Gains and Standout US Growth Helps Entersekt Solidify Market Position

16.8.2023 12:00:00 EEST | Business Wire | Press release

Share

Entersekt, a global leader in transaction authentication solutions for financial fraud prevention, today announced strong growth in both revenue and number of customers, fueled by continued US expansion and strategic partnerships. Since the investment by Accel-KKR in fiscal 2022, Entersekt has seen its business outside of South Africa accelerate rapidly with contracted annual recurring revenue increase by 191%, and nearly 220% growth in US-based customers in fiscal 2023 alone.

“Our solid growth in a difficult global business climate is testament to Entersekt’s innovation and expertise addressing emerging fraud threats,” said Schalk Nolte, Entersekt CEO. “Our reputation of delivering the highest level of security to financial institutions across all digital channels without compromising user experience is capturing the attention of decision makers – many of whom now recognize the urgent need to adopt more robust authentication methods to replace the traditional approaches that are proving to be vulnerable to increasingly sophisticated fraud attempts.”

“We are particularly pleased with our performance in the US which is nearing hypergrowth. The region remains a key focus for the year ahead and we have identified key partners and talent who are well known in the industry to help us to accelerate the current trajectory. The market has shown itself eager to adopt our technology which has a proven track record with financial institutions around the world,” Nolte explained.

“As fraud and financial crime continues to threaten financial institutions around the world, the opportunity for innovative technology firms to help mitigate these risks is greater than ever,” said Julie Conroy, Head of Risk Insights at Datos Insights. “Entersekt’s steady growth and expansion is a key indicator of the appetite for FIs of all sizes to seek solutions that can reduce fraud while ensuring an optimal user experience.”

Fiscal 2023 Performance Highlights

Market-leading fraud prevention Innovations
The Entersekt team continued to innovate well ahead of the industry curve, with three new patents granted in FY2023, adding to the more than 60 existing technology patents. These include Context Aware™ Authentication which is the first cross-channel fraud prevention to consider the originating channel, the transaction context, the analysis and orchestration of both active and silent risk signals, the available authentication mechanisms, as well as the customer’s choice to determine the most appropriate authentication journey - all in real-time.

“Many banks continue to struggle with siloed authentication mechanisms, with different solutions for online banking, in-branch offerings, call centers, digital payments and open banking, with each using its own authentication technology. We're providing the ability to break down all those silos and have one common authentication platform across all the various channels. Not only does this provide a much better user and customer experience, but also helps orchestrate all that data to help banks make better decisions,” Nolte said.

New strategic channel and technology partnerships
The Entersekt team continued to solidify new partnerships in all regions, improving it’s go-to-market scale and creating new market opportunities. By supporting pre-integration, these partnerships enabled banks to quickly and easily deploy Entersekt’s state-of-the-art authentication technology. Most recently, Entersekt’s biometric authentication technology was integrated into Q2’s Digital Banking Platform, adding biometric authentication capabilities to the Q2 online and mobile banking applications.

Expanded senior management
To support the significant growth and opportunity in the US market, Entersekt made ten new director, VP or C-level hires in the US in FY23. Its executive team and company headquarters is now based both in the US and South Africa, showcasing the importance of and commitment to regional representation.

Three new C-level appointments, all with decades of leadership experience, include Matt Loos as Chief Revenue Officer, Pradheep Sampath as Chief Product Officer and Frank Moreno as Chief Marketing Officer.

  • Loos joins Entersekt with over 20 years of leadership experience at companies like Fifth Third Bank, Cardinal Commerce and Mastercard.
  • Sampath has led new product initiatives for over 20 years, scaling SaaS, mobile and API-based products for companies like ID.me and GXS.
  • Moreno’s experience includes senior marketing leadership roles spanning over 20 years with tech companies such as Bottomline and Datawatch.

More growth on the horizon
Looking ahead, Nolte said the industry must prepare for the continued challenges of account takeover fraud schemes and authorized push payment fraud, saying the rise of real-time payments, particularly through mobile apps, has introduced a need for faster and more effective fraud detection mechanisms.

“Our vision for the future is centered around becoming a leading force in the digital landscape, revolutionizing the way people conduct secure transactions on digital platforms. With the backing of our US-based investors, key partners and a customer-centric approach, we are poised for exceptional success in the year ahead and beyond,” Nolte said.

About Entersekt
Entersekt ensures that digital financial transactions are secure and free from unnecessary friction. The company provides a single cross-channel platform for financial services institutions to meet authentication requirements and optimize user experiences. With a range of options available for deployment and configuration, Entersekt’s solutions are fully customizable across all channels and devices. A strong track record of over ten years’ working with leading financial services institutions across the United States, Europe, and Africa, combined with multiple patented security innovations, has established Entersekt as a global industry leader in authentication. Backed by companies like Silicon Valley-based Accel-KKR, one of the world’s top private equity firms, Entersekt continues to expand its footprint across key regions. For more information, visit entersekt.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Frank Moreno
Chief Marketing Officer
frank@entersekt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye